ArrePath

United States - Princeton, New Jersey

• 03/03/2022
• Seed
• $20,000,000

ArrePath is a biotech company discovering and developing new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state of the art technologies and novel strategies.

We apply world-class science and innovation in imaging and AI / ML technologies to identify and develop novel drugs to address global health issues.

Our advanced machine learning (ML) and imaging-based drug discovery platform enables a rapid and efficient identification of new drug classes with desired activity profiles and clinical utility, coupled with a deep understanding of mechanism of action at the outset of the discovery process.

Related People

Lloyd PayneFounder

United Kingdom -

Drug Discovery executive and leader, AMR and anti-infectives specialist, CEO at ArrePath Inc., a Princeton University spin-out biotech company combining ML- and imaging-technologies to discovery and develop new classes of anti-infectives.

Advisor to the Novo REPAIR Impact Fund and the AMR Action Fund.

Formerly Head of Anti-infectives at Evotec SE and founding CEO of specialist Anti-infectives company, Euprotec (founded 2008, built and successfully sold to Evotec, 2014).

Working with companies and organisations dedicated to the discovery and development of new anti-infective therapies and vaccines across multiple sectors, including Biotech, CRO, academia, Public-Private Partnerships, VC / Investors, and charities.

LinkedIn https://www.linkedin.com/in/lloyd-payne/?originalSubdomain=uk